ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported 2024 results sharing progress with ...

The candidates must make sure that they enter valid details associated with the NDA eligibility criteria in the application form to avoid cancellation of the candidature. Here are the key ...

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Union Public Service Commission (UPSC) may soon release the notification for the NDA, NA (I) Exam 2025. According to the UPSC calendar, the application process will start on December 11 ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...

The purpose of this meeting is to review the XRx-026 program and its readiness for submission of a New Drug Application (“NDA”) to gain marketing approval for XORLO ™ in the US using the FDA ...

The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for relacorilant to treat patients with Cushing syndrome (hypercortisolism). Relacorilant is a cortisol ...